Chromocell Therapeutics (CHRO) Stock Price, News & Analysis

Company Overview

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

Key Stats

• Today's Range: $0.91 to $1.10
• 50-Day Range: $1.07 to $2.18
• 52-Week Range: $0.45 to $3.80
• Volume: 641,585 shs
• Average Volume: 432,256 shs
• Market Capitalization: $6.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

CHRO Stock Analysis - Frequently Asked Questions

How have CHRO shares performed this year?

Chromocell Therapeutics' stock was trading at $0.6410 at the start of the year. Since then, CHRO stock has increased by 56.8% and is now trading at $1.0050.
View the best growth stocks for 2025 here.

When did Chromocell Therapeutics IPO?

Chromocell Therapeutics (CHRO) raised $7 million in an IPO on Friday, February 16th 2024. The company issued 1,100,000 shares at $6.00 per share.

How do I buy shares of Chromocell Therapeutics?

Shares of CHRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 5/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:CHRO
• Previous Symbol: NYSE:CHRO
• CIK: 1919246
• Web: chromocell.com
• Phone: 732-514-2636
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-7,380,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -453.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.60
• Quick Ratio: 0.60

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.65) per share
• Price / Book: -0.62

Miscellaneous

• Outstanding Shares: 6,104,000
• Free Float: 5,039,000
• Market Cap: $6.23 million
• Optionable: N/A
• Beta: 4.59